Administration of zoledronic acid enhances the effects of docetaxel on growth of prostate cancer in the bone environmentReport as inadecuate




Administration of zoledronic acid enhances the effects of docetaxel on growth of prostate cancer in the bone environment - Download this document for free, or read online. Document in PDF available to download.

BMC Cancer

, 6:15

First Online: 17 January 2006Received: 02 November 2005Accepted: 17 January 2006DOI: 10.1186-1471-2407-6-15

Cite this article as: Brubaker, K.D., Brown, L.G., Vessella, R.L. et al. BMC Cancer 2006 6: 15. doi:10.1186-1471-2407-6-15

Abstract

BackgroundAfter development of hormone-refractory metastatic disease, prostate cancer is incurable. The recent history of chemotherapy has shown that with difficult disease targets, combinatorial therapy frequently offers the best chance of a cure. In this study we have examined the effects of a combination of zoledronic acid ZOL, a new-generation bisphosphonate, and docetaxel on LuCaP 23.1, a prostate cancer xenograft that stimulates the osteoblastic reaction when grown in the bone environment.

MethodsIntra-tibial injections of LuCaP 23.1 cells were used to generate tumors in the bone environment, and animals were treated with ZOL, docetaxel, or a combination of these. Effects on bone and tumor were evaluated by measurements of bone mineral density and histomorphometrical analysis.

ResultsZOL decreased proliferation of LuCaP 23.1 in the bone environment, while docetaxel at a dose that effectively inhibited growth of subcutaneous tumors did not show any effects in the bone environment. The combination of the drugs significantly inhibited the growth of LuCaP 23.1 tumors in the bone.

ConclusionIn conclusion, the use of the osteolysis-inhibitory agent ZOL in combination with docetaxel inhibits growth of prostate tumors in bone and represents a potential treatment option.

AbbreviationsCaPprostate cancer, ZOL: zoledronic acid, DOC: docetaxel, BPs: bisphosphonates, SC: subcutaneously, BMD: bone mineral density, BHM: bone histomorphometry, BV-TV: bone volume in tissue volume, TuV-TV: tumor volume in tissue volume, Tb.Th.: trabecular thickness, Tb.N.: trabecular number, Tb.Sp.: trabecular separation, Ob.Pm.-BPm.: osteoblast perimeter per bone perimeter, N.Oc.-BS: osteoclast number per bone surface, Os.S-BS: osteoid surface per bone surface, Os.Th.: osteoid thickness

Electronic supplementary materialThe online version of this article doi:10.1186-1471-2407-6-15 contains supplementary material, which is available to authorized users.

Download fulltext PDF



Author: Kristen D Brubaker - Lisha G Brown - Robert L Vessella - Eva Corey

Source: https://link.springer.com/







Related documents